Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma

Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)

NCT02335424 ·Status: COMPLETED ·Phase: PHASE2

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

NCT07129993 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

NCT03473730 ·Status: COMPLETED ·Phase: EARLY_PHASE1

Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy

NCT03697850 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy

NCT03345134 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer

NCT00872495 ·Status: RECRUITING

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

NCT01050504 ·Status: RECRUITING

To Detect the Sensitivity of the UroMark Assay

NCT02781428 ·Status: COMPLETED

A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)

NCT02951767 ·Status: COMPLETED ·Phase: PHASE2

The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer

NCT03577132 ·Status: UNKNOWN ·Phase: NA

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

NCT03978624 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

NCT04660344 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue

NCT02379429 ·Status: RECRUITING

CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

NCT03628716 ·Status: COMPLETED ·Phase: PHASE2

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

NCT03854474 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

NCT03375307 ·Status: SUSPENDED ·Phase: PHASE2

Phase II Study of TKI258 in Advanced Urothelial Carcinoma

NCT00790426 ·Status: COMPLETED ·Phase: PHASE2

Assessment of Supportive Care and Educational Needs to Guide Quality Care Improvements for Patients With Locally Advanced and Metastatic Bladder Cancer

NCT06412874 ·Status: COMPLETED

Evaluation of PD-L1 Expression and Immune Infiltration in High-risk Non Muscle Invasive Bladder Cancer

NCT04726735 ·Status: COMPLETED

Trial of Prehabilitation in Vulnerable Patients Undergoing Cystectomy for Bladder Cancer

NCT01840137 ·Status: COMPLETED ·Phase: NA

Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder

NCT02745301 ·Status: COMPLETED

A Prospective, Multicenter Cohort Study of Urinary Exosome lncRNAs for Preoperative Diagnosis of Lymphatic Metastasis in Patients With Bladder Cancer

NCT05270174 ·Status: UNKNOWN

TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

NCT01328574 ·Status: COMPLETED ·Phase: PHASE2

Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

NCT06138561 ·Status: RECRUITING

Prospective and Multicenter Italian Registry of Locally Advanced-Metastatic Urothelial Carcinoma

NCT06235268 ·Status: RECRUITING